Dr Danielle Bond

Dr Danielle Bond

Research Associate

School of Biomedical Sciences and Pharmacy

Career Summary

Biography

Dr Bond is an Early Career Research Associate in the School of Biomedical Sciences and Pharmacy. She is based at the Central Coast campus of the University of Newcastle, working within the cancer research hub at Ourimbah in association with the Hunter Cancer Research Alliance (HCRA) and HMRI. She uses cutting-edge technology to test novel synthetic and natural products for the treatment of pancreatic cancer, as part of the Pancreatic Cancer Research Group, and is identifying blood markers in prostate cancer patients to help predict patient prognosis to current and new cancer treatments.

Dr Bond is primarily interested in pancreatic cancer as it has a very low survival rate and prostate cancer due to its high incidence rate among Australian men. She completed her PhD in Medical Biochemistry, which focused on breast and prostate cancers at the University of Newcastle in 2015. Since 2015, Dr Bond has been testing novel, natural and synthetic compounds as anti-pancreatic cancer agents and has been investigating blood markers for prostate cancer.

She has presented her work at both national and international conferences and continues to publish her findings, has helped organise local scientific meetings and has been an RHD representative for the school research committee. Dr Bond has received pilot grant funding through the Faculty of Health at the University of Newcastle and project funding from HMRI.


Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Breast Cancer
  • Drug Discovery
  • Pancreatic Cancer
  • Prostate Cancer
  • Tetraspanins
  • micro-RNA

Languages

  • English (Mother)

Fields of Research

Code Description Percentage
111201 Cancer Cell Biology 80
111204 Cancer Therapy (excl. Chemotherapy and Radiation Therapy) 20

Professional Experience

UON Appointment

Title Organisation / Department
Research Associate University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
Casual Academic University of Newcastle
School of Environmental and Life Sciences
Australia

Academic appointment

Dates Title Organisation / Department
6/04/2015 - 31/12/2016 Research Associate Faculty of Science and Information Technology, The University of Newcastle | Australia
Environmental and Life Sciences
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (6 outputs)

Year Citation Altmetrics Link
2017 Bhuyan DJ, Sakoff J, Bond DR, Predebon M, Vuong QV, Chalmers AC, et al., 'In vitro anticancer properties of selected Eucalyptus species', IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 53 604-615 (2017) [C1]
DOI 10.1007/s11626-017-0149-y
Co-authors Jennette Sakoff, Ian Vanaltena, Michael Bowyer, Vanquan Vuong, C Scarlett, Anita Chalmers
2017 Bhuyan DJ, Vuong QV, Bond DR, Chalmers AC, van Altena IA, Bowyer MC, Scarlett CJ, 'Exploring the Least Studied Australian Eucalypt Genera: Corymbia and Angophora for Phytochemicals with Anticancer Activity against Pancreatic Malignancies', CHEMISTRY & BIODIVERSITY, 14 (2017) [C1]
DOI 10.1002/cbdv.201600291
Citations Scopus - 1Web of Science - 1
Co-authors Vanquan Vuong, Ian Vanaltena, Michael Bowyer, Anita Chalmers, C Scarlett
2017 Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, et al., 'Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.', Scientific Reports, 7 15987-15987 (2017) [C1]
DOI 10.1038/s41598-017-15993-3
Co-authors Judith Weidenhofer, Rodney Scott, Leonie Ashman, Matt Dun
2016 Weidenhofer JC, Colvin EK, Bond DR, Scarlett CJ, 'Animal models of pancreatic cancer and their application in clinical research', Gastrointestinal Cancer : Targets and Therapy, 2016 31-39 (2016) [C1]
Co-authors C Scarlett, Judith Weidenhofer
2014 Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al., 'ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer', American Journal of Pathology, 184 3156-3162 (2014) [C1]

© 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mecha... [more]

© 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of nerve growth factor (proNGF) is overexpressed in prostate cancer and involved in the ability of prostate cancer cells to induce axonogenesis. A series of 120 prostate cancer and benign prostate hyperplasia (BPH) samples were analyzed by IHC for proNGF. ProNGF was mainly localized in the cytoplasm of epithelial cells, with marked expression in cancer compared with BPH. Importantly, the proNGF level positively correlated with the Gleason score (n = 104, t < inf > B < /inf > = 0.51). A higher level of proNGF was observed in tumors with a Gleason score of =8 compared with a Gleason score of 7 and 6 (P < 0.001). In vitro, proNGF was detected in LNCaP, DU145, and PC-3 prostate cancer cells and BPH-1 cells but not in RWPE-1 immortalized nontumorigenic prostate epithelial cells or primary normal prostate epithelial cells. Co-culture of PC12 neuronal-like cells or 50B11 neurons with PC-3 cells resulted in neurite outgrowth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that prostate cancer cells can induce axonogenesis via secretion of proNGF. These data reveal that ProNGF is a biomarker associated with high-risk prostate cancers and a potential driver of infiltration by nerves.

DOI 10.1016/j.ajpath.2014.08.009
Citations Scopus - 9Web of Science - 7
Co-authors Phillip Jobling, Lisa Lincz, Marjorie Walker, Rick Thorne, Hubert Hondermarck
2014 Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
DOI 10.2217/bmt.14.2
Co-authors Judith Weidenhofer, Kathryn Skelding
Show 3 more journal articles

Conference (14 outputs)

Year Citation Altmetrics Link
2016 Goldsmith C, Bond D, Stathopoulos C, Roach P, Scarlett C, 'THE OLIVE PHENOLIC COMPOUNDS APIGENIN, LUTEOLIN AND OLEUROPEIN INDUCE CELL-CYCLE ARREST AND APOPTOSIS IN PANCREATIC CANCER CELLS IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors C Scarlett
2016 Jankowski H, Brzozowski J, Goldie B, Bond D, Munro B, Scarlett C, et al., 'PROSTATE CANCER EXTRACELLULAR VESICLES: FRIEND OR FOE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Judith Weidenhofer, C Scarlett
2016 Bond D, Thuong PT, Thiha D, Khoi NM, Cuong NM, Weidenhofer J, Scarlett C, 'PURE COMPOUNDS FROM VIETNAMESE MEDICINAL PLANTS SHOW PROMISING ANTI-PANCREATIC CANCER ACTIVITY IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Judith Weidenhofer, C Scarlett
2016 Brzozowski J, Jankowski H, Munro B, Predebon M, Bond D, Scarlett C, et al., 'ALTERATIONS IN LIPID COMPOSITION OF NORMAL AND TUMOR-DERIVED PROSTATE EXTRACELLULAR VESICLES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Judith Weidenhofer, C Scarlett
2016 Jankowski H, Goldie B, Brzozowski J, Munro B, Bond D, Scarlett C, et al., 'TETRASPANIN CD9 MODIFIES EXTRACELLULAR VESICLE NUCLEIC ACID CARGO IN PROSTATE CELL LINES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors C Scarlett, Judith Weidenhofer
2015 Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding KA, Weidenhofer J, 'Differences in extracellular vesicle nucleic acid content show promise as prostate cancer biomarkers', Boston, MA (2015) [O1]
Co-authors Judith Weidenhofer, Kathryn Skelding, C Scarlett
2015 Brzozowski J, Coldie B, Jankowski H, Bond D, Scarlett C, Dun M, et al., 'THE EFFECTS OF ALTERED CD9 AND CD151 EXPRESSION ON PROSTATE EXOSOMES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Kathryn Skelding, Matt Dun, C Scarlett, Judith Weidenhofer
2015 Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding K, Weidenhofer J, 'PROSTATE CANCER BIOMARKERS: ARE EXTRACELLULAR VESICLES THE SOLUTION?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Judith Weidenhofer, C Scarlett, Kathryn Skelding
2015 Bond D, Turner A, Richmond R, Sadeqzadeh E, Vuong Q, Bhuyan D, et al., 'THE SEARCH FOR NOVEL TREATMENT AGENTS FOR PANCREATIC CANCER: TALES FROM THE LAND AND SEA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Ian Vanaltena, Vanquan Vuong, Anita Chalmers, Michael Bowyer, Troy Gaston, Jennette Sakoff, C Scarlett, Judith Weidenhofer
2015 Predebon M, Bond D, Brzozowski J, Jankowski H, Deane F, Tarleton M, et al., 'A BISPIDINONE ANALOGUE INDUCES AN APOPTOSIS-MEDIATED CYTOTOXIC EFFECT ON PANCREATIC CANCER CELLS IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Adam Mccluskey, C Scarlett, Michael Bowyer, Judith Weidenhofer
2014 Bond DR, Passfield C, Cairns M, Ashman LK, Weidenhofer J, 'Posttranscriptional regulation of tetraspanins CD151 & CD9 in breast & prostate cancers', CANCER RESEARCH, San Diego, CA (2014) [E3]
DOI 10.1158/1538-7445.AM2014-4364
Co-authors Leonie Ashman, Murray Cairns, Judith Weidenhofer
2013 Weidenhofer J, Bond D, Copeland B, Ashman L, 'Tetraspanin protein turnover rates vary in prostate cancer cell lines', BJU INTERNATIONAL (2013) [E3]
Co-authors Leonie Ashman, Judith Weidenhofer
2013 Bond D, Cairns M, Ashman L, Weidenhofer J, 'Post-transcriptional regulation of CD151 & CD9 by miRNAs in prostate cancer', BJU INTERNATIONAL (2013) [E3]
Co-authors Judith Weidenhofer, Leonie Ashman, Murray Cairns
2012 Bond DR, Cairns MJ, Ashman LK, Weidenhofer JC, 'Investigating micro-RNA regulation of tetraspanins CD151 and CD9 in prostate cancer', Febs Journal, Seville, Spain (2012) [E3]
Co-authors Judith Weidenhofer, Murray Cairns, Leonie Ashman
Show 11 more conferences
Edit

Grants and Funding

Summary

Number of grants 2
Total funding $405,000

Click on a grant title below to expand the full details for that specific grant.


20141 grants / $400,000

Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$400,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jude Weidenhofer, Doctor Kathryn Skelding, Doctor Matt Dun, Ms Belinda Goldie, Doctor Danielle Bond
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2017
GNo G1400921
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20111 grants / $5,000

Investigation of miRNA targeting of tetraspanins CD151 and CD9 in breast cancer $5,000

Funding body: The Faculty of Health, The University of Newcastle

Funding body The Faculty of Health, The University of Newcastle
Project Team

Judith Weidenhofer, Murray Cairns & Danielle Bond

Scheme Faculty of Health Pilot Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Dr Danielle Bond

Positions

Research Associate
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Casual Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Casual Academic
School of Environmental and Life Sciences
Faculty of Science

Contact Details

Email danielle.bond@newcastle.edu.au
Phone (02) 43484045

Office

Room SO-103
Building Science Offices Building
Location Ourimbah
10 Chittaway Road
Ourimbah, NSW 2258
Australia
Edit